About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

FDA Investigates Deaths of Patients on Antipsychotic Drug

Two patients died days after receiving Zyprexa injections
WEDNESDAY, June 19 (HealthDay News) -- Following the deaths of two patients three to four days after receiving a dose of Zyprexa Relprevv (olanzapine pamoate) via intramuscular injection, the U.S. Food and Drug Administration is conducting an investigation into the possible cause.
The patients were well outside the three-hour window of monitoring required by the antipsychotic drug's Risk Evaluation and Mitigation Strategy (REMS), but were found to have very high blood levels of olanzapine after death.
In addition to the three-hour monitoring period, REMS protocol requires patients to receive injections only at REMS-certified facilities and to be accompanied home after the monitoring period. The drug's label warns against possible post-injection delirium sedation syndrome, in which the agent enters the blood too quickly and causes heavy sedation (possibly coma) and/or delirium.
According to the agency, "FDA is providing this information to health care professionals while it continues its investigation. If therapy with Zyprexa Relprevv is started or continued in patients, health care professionals should follow the REMS requirements and drug label recommendations. Patients and caregivers should talk to their health care professional(s) about any questions or concerns."
More Information (http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm357601.htm?source=govdeliver )
Health Headlines
If Kids Think Someone's Watching, They're More Likely to Wash Their HandsView in a lightbox
Spring Cleaning Safety TipsView in a lightbox
Ragwitek Approved for Adult Ragweed AllergyView in a lightbox
Restaurants in Poor Areas Push Unhealthy Foods, Study FindsView in a lightbox
Certain Sedatives Tied to Breathing Problems in Older COPD PatientsView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices